Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares Issued Shares Outstanding Shares Outstanding

Ratios

Contineum Therapeutics (CTNM) Long-Term Debt Repayments (2023)

Contineum Therapeutics has reported Long-Term Debt Repayments over the past 1 years, most recently at $3.1 million for Q2 2023.

Quarterly results put Long-Term Debt Repayments at $3.1 million for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was $3.1 million (changed N/A YoY), and the annual figure for FY2023 was $3.8 million, changed.
Long-Term Debt Repayments for Q2 2023 was $3.1 million at Contineum Therapeutics, up from $625000.0 in the prior quarter.
Over the last five years, Long-Term Debt Repayments for CTNM hit a ceiling of $3.1 million in Q2 2023 and a floor of $625000.0 in Q1 2023.